• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Dermatologist’s Role in Minimizing Antibiotic Resistance


Efforts to lessen the arbitrary use of antibiotics that contribute to the development of antibiotic resistance are urgently needed, as this growing concern threatens the effective treatment of infectious diseases globally.

These excerpts from an interview with James Q. Del Rosso, DO, feature him speaking about antibiotic resistance in dermatology, the importance of impeding resistance, and how dosing outside of the mutant selection window can hinder the formation of multidrug-resistant mutants. 

Author Information

James Q. Del Rosso, DO

James Q. Del Rosso, DO
Research Director
JDR Dermatology Research/Thomas Dermatology
Las Vegas, Nevada
Adjunct Clinical Professor (Dermatology)
Touro University Nevada
Henderson, Nevada

James Q. Del Rosso, DO, is an internationally renowned speaker and educator and the recipient of the American Academy of Dermatology (AAD) Lifetime Achievement Award for his contributions to the field of dermatology. James Q. Del Rosso, DO, is the Research Director and Principal Investigator at JDR Dermatology Research and is a dermatologist in private practice in Las Vegas, Nevada; he has been board certified since 1988.


James Q. Del Rosso, DO, is a consultant for Aclaris, Almirall, Athenex, BioPharmX, Cutanea, Dermira, Ferndale Laboratories, Foamix Pharmaceuticals Inc., Galderma, LEO Pharma, Menlo Therapeutics, Novan, Ortho, Pfizer, Promius, Sanofi/Regeneron, SkinFix, and Sun Pharma; he has received research support from Aclaris, Almirall, Athenex, BioPharmX, Botanix, Celgene, Cutanea, Dermira, Foamix Pharmaceuticals Inc., Galderma, Genentech, LEO Pharma, Menlo Therapeutics, Novan, Ortho, Promius, Regeneron, Sun Pharma, and Thync; he participates in speakers bureaus for honoraria from Aclaris, Almirall, Celgene, Galderma, Genentech, LEO Pharma, Ortho, Pfizer, Promius, Sanofi/Regeneron, and Sun Pharma.


1. Barbieri JS, et al. J Am Acad Dermatol. 2017;77(3):456-463.

2. Coates P, et al. Br J Dermatol. 2002;146(5):840-848.

3. Day T, Read AF. PLoS Comput Biol. 2016;28(12,1):e1004689.

4. Del Rosso JQ, et al. J Clin Aesthet Dermatol. 2016;9(4):18-24.

5. Del Rosso JQ, Zeichner JA. Dermatol Clin. 2016;34(2):167-173.

6. Drlica K. J Antimicrob Chemother. 2003;52(1):11-17.

7. Eady EA, et al. Br J Dermatol. 1989;121(1):51-57.

8. Fong W, Drlica K, eds. Antimicrobial Resistance and Implications for the Twenty-First Century. New York: Springer; 2008.

9. Kouyos RD, et al. Proc Bio Sci. 2014;281(1794):20140566.

10. Martinez JL, Baquero F. Ups J Med Sci. 2014;119(2):68-77.

11. Mills O Jr, et al. Acta Derm Venereol. 2002;82(4):260-265.

12. Nast A, et al. J Eur Acad Dermatol Venereol. 2016;30(8):1261-1268.

13. Ross JI, et al. Br J Dermatol. 2003;148(3):467-478.

14. Skidmore R, et al. Arch Dermatol. 2003;139(4):459-464.

15. World Health Organization. Antimicrobial resistance: Global report on surveillance 2014. Geneva, Switzerland: WHO; 2014.

16. Wright GD. BMC Biology. 2010;8:123.

17. Zaenglein AL, et al. J Am Acad Dermatol. 2016;74(5):945-973.e33.


The activity is sponsored by Foamix Pharmaceuticals Inc.


Related Videos
© 2024 MJH Life Sciences

All rights reserved.